Update on systemic treatment in early triple negative breast cancer

被引：29

作者：

Nunez Abad, Martin ^{[1
]}

Calabuig-Farinas, Silvia ^{[2
,4
,5
,6
,7
]}

Lobo de Mena, Miriam ^{[1
]}

Sanz de Bremond, Maria Jose Godes ^{[1
]}

Garcia Gonzalez, Clara ^{[1
]}

Torres Martinez, Susana ^{[2
,4
]}

Angel Garcia-Garcia, Jose ^{[8
]}

Iranzo Gonzalez-Cruz, Vega ^{[1
,2
,3
]}

Camps Herrero, Carlos ^{[1
,2
,4
,6
,7
]}

机构：

[1] Univ Gen Hosp Valencia, Dept Med Oncol, Tres Cruces 2, Valencia 46014, Spain

[2] CIBERONC, Madrid, Spain

[3] Univ Valencia, Dept Med, Valencia, Spain

[4] Univ Gen Hosp Valencia, Gen Univ Hosp Res Fdn, Mol Oncol Lab, Valencia, Spain

[5] Univ Valencia, Dept Pathol, Valencia, Spain

[6] Principe Felipe Res Ctr, Mixed Unit TRIAL, Valencia, Spain

[7] Gen Univ Hosp Valencia Res Fdn, Valencia, Spain

[8] Univ Gen Hosp Valencia, Dept Pathol Anat, Valencia, Spain

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2021年 / 13卷

关键词：

chemotherapy; immunotherapy; neoadjuvant therapy; precision medicine; systemic treatment; triple negative breast cancer; TUMOR-INFILTRATING LYMPHOCYTES; STANDARD NEOADJUVANT CHEMOTHERAPY; SURGICAL ADJUVANT BREAST; PHASE-III TRIAL; OPEN-LABEL; PREOPERATIVE DOXORUBICIN; ANDROGEN RECEPTOR; PROGNOSTIC VALUE; PACLITAXEL; CYCLOPHOSPHAMIDE;

D O I：

10.1177/1758835920986749

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Triple negative breast cancer (TNBC) is a heterogeneous disease representing about 15% of all breast cancers. TNBC are usually high-grade histological tumors, and are generally more aggressive and difficult to treat due to the lack of targeted therapies available, and chemotherapy remains the standard treatment. There is a close relationship between pathological complete response after chemotherapy treatment and higher rates of disease-free survival and overall survival. In this review of systemic treatment in early triple negative breast cancer, our purpose is to analyze and compare different therapies, as well as to highlight the novelties of treatment in this breast cancer subtype.

引用

页数：18

共 97 条

[1]

Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0

[2] A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study [J].

Alba, E. ;

Chacon, J. I. ;

Lluch, A. ;

Anton, A. ;

Estevez, L. ;

Cirauqui, B. ;

Carrasco, E. ;

Calvo, L. ;

Segui, M. A. ;

Ribelles, N. ;

Alvarez, R. ;

Sanchez-Munoz, A. ;

Sanchez, R. ;

Lopez Garcia-Asenjo, J. A. ;

Rodriguez-Martin, C. ;

Escudero, M. J. ;

Albanell, J. .

BREAST CANCER RESEARCH AND TREATMENT, 2012, 136 (02) :487-493

[3]

Aogi K, 2014, J CLIN ONCOL, V32, P1017

[4] ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC) [J].

Bardia, A. ;

Tolaney, S. M. ;

Loirat, D. ;

Punie, K. ;

Oliveira, M. ;

Rugo, H. S. ;

Brufsky, A. ;

Kalinsky, K. ;

Cortes, J. ;

O'Shaughnessy, J. ;

Dieras, V. C. ;

Carey, L. A. ;

Gianni, L. ;

Piccart, M. ;

Loibl, S. ;

Goldenberg, D. ;

Hong, Q. ;

Olivo, M. S. ;

Itri, L. M. ;

Hurvitz, S. A. .

ANNALS OF ONCOLOGY, 2020, 31 :S1149-S1150

[5] Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27 [J].

Bear, HD ;

Anderson, S ;

Smith, RE ;

Geyer, CE ;

Mamounas, EP ;

Fisher, B ;

Brown, AM ;

Robidoux, A ;

Margolese, R ;

Kahlenberg, MS ;

Paik, S ;

Soran, A ;

Wickerham, DL ;

Wolmark, N .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (13) :2019-2027

[6] The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from national surgical adjuvant breast and bowel project protocol B-27 [J].

Bear, HD ;

Anderson, S ;

Brown, A ;

Smith, R ;

Mamounas, EP ;

Fisher, B ;

Margolese, R ;

Theoret, H ;

Soran, A ;

Wickerham, DL ;

Wolmark, N .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (22) :4165-4174

[7] Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology) [J].

Blum, Joanne L. ;

Flynn, Patrick J. ;

Yothers, Greg ;

Asmar, Lina ;

Geyer, Charles E., Jr. ;

Jacobs, Samuel A. ;

Robert, Nicholas J. ;

Hopkins, Judith O. ;

O'Shaughnessy, Joyce A. ;

Dang, Chau T. ;

Gomez, Henry Leonidas ;

Fehrenbacher, Louis ;

Vukelja, Svetislava J. ;

Lyss, Alan P. ;

Paul, Devchand ;

Brufsky, Adam M. ;

Jeong, Jong-Hyeon ;

Colangelo, Linda H. ;

Swain, Sandra M. ;

Mamounas, Eleftherios P. ;

Jones, Stephen E. ;

Wolmark, Norman .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (23) :2647-+

[8] RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer [J].

Brufsky, Adam M. ;

Hurvitz, Sara ;

Perez, Edith ;

Swamy, Raji ;

Valero, Vicente ;

O'Neill, Vincent ;

Rugo, Hope S. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) :4286-4293

[9] The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis [J].

Caramelo, Olga ;

Silva, Cristina ;

Caramelo, Francisco ;

Frutuoso, Cristina ;

Almeida-Santos, Teresa .

HEREDITARY CANCER IN CLINICAL PRACTICE, 2019, 17 (1)

[10] Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Cardoso, F. ;

Kyriakides, S. ;

Ohno, S. ;

Penault-Llorca, F. ;

Poortmans, P. ;

Rubio, I. T. ;

Zackrisson, S. ;

Senkus, E. .

ANNALS OF ONCOLOGY, 2019, 30 (08) :1194-1220

← 1 2 3 4 5 6 7 8 9 10 →